Protocatechuamide

Protocatechuamide

SCHEMBL1128716

NC(=O)c1ccc(O)c(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.65
CA2 P00918 5/20 0.62
CA12 O43570 4/20 0.62
CA1 P00915 4/20 0.62
CA7 P43166 4/20 0.62
CA9 Q16790 4/20 0.62
CA14 Q9ULX7 4/20 0.62
KDM4E B2RXH2 2/20 0.62
GAA P10253 2/20 0.62
MAPT P10636 2/20 0.62
POLB P06746 1/20 0.62
CA4 P22748 1/20 0.62
CA6 P23280 1/20 0.62
PTGS2 P35354 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
HDAC6 Q9UBN7 1/20 0.56
DBH P09172 1/20 0.54
RECQL P46063 1/20 0.54
XDH P47989 1/20 0.54
PARP1 P09874 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Protocatechuamide SCHEMBL28613093 0.98 LCK (0.63) LCKCA2CA12CA1CA7
Protocatechuamide SCHEMBL3330438 0.84 CA12 (0.50) LCKCA2CA12CA1CA7
SCHEMBL28842093 0.81 CA12 (0.58) LCKCA2CA12CA1CA7
SCHEMBL11337357 0.81 LCK (0.55) LCKCA2CA12CA1CA7
SCHEMBL1805788 0.81 LCK (0.55) LCKCA2CA12CA1CA7
SCHEMBL926368 0.81 LCK (0.55) LCKCA2CA12CA1CA7
SCHEMBL3015286 0.81 LCK (0.55) LCKCA2CA12CA1CA9
SCHEMBL5595306 0.81 LCK (0.55) LCKCA2CA12CA1CA7
SCHEMBL1489540 0.81 CA12 (0.58) LCKCA2CA12CA1CA7
SCHEMBL31746203 0.81 CA12 (0.57) LCKCA2CA12CA1CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122059965-A Preparation method of Icotinib hydrochloride 重庆圣华曦药业股份有限公司 2026-05-19 CN claimed
CN-119161159-A High-strength black sand ceramic for furniture and preparation process thereof 馆陶县陶山黑陶科技有限公司 2024-12-20 CN claimed
CN-118459943-B Preparation method of hydrophobic polyester tire 山东鸿泰新材料有限公司 2024-09-27 CN claimed
CN-118459943-A Preparation method of hydrophobic polyester tire 山东鸿泰新材料有限公司 2024-08-09 CN claimed
US-20230255906-A1 Targeting Serpin B9 in Cancer THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2023-08-17 US claimed
CN-115427142-A Perovskite solar cell provided with adsorbing material for adsorbing toxic substances 洛桑联邦理工学院(EPFL) 2022-12-02 CN claimed
US-20200205541-A1 METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AROMATIC COMPOUND L'OREAL (FR) 2020-07-02 US claimed
EP-1511710-B1 COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER S DISEASE, TYPE 2 DIABETES, AND PARKINSON S DISEASE PROTEOTECH INC (US) 2013-11-20 EP claimed
US-20130298933-A1 METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AROMATIC COMPOUND L'OREAL (FR) 2013-11-14 US claimed
CN-102863395-A Novel method for synthesizing Erlotinib BEIJING LIUSHENGHE MEDICAL TECHNOLOGY CO LTD 2013-01-09 CN claimed
US-6509352-B1 Selectively act on cannabinoid receptors, particularly on peripheral type cannabinoid receptors, and have fewer side effects on the central nervous system, having great immunosuppressive action, anti-inflammatory action or JAPAN TOBACCO INC. (JP) 2003-01-21 US claimed
EP-0900781-B1 Phenolic acid amides of hydroxy substituted benzylamines HAARMANN & REIMER GMBH (DE) 2002-03-20 EP claimed
EP-1142877-A1 2-OXOQUINOLINE COMPOUNDS AND MEDICINAL USES THEREOF JAPAN TOBACCO INC. (JP) 2001-10-10 EP claimed
EP-1068187-A1 PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION ABBOTT LABORATORIES (US) 2001-01-17 EP claimed
WO-1999051580-A1 PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION ABBOTT LABORATORIES (US) 1999-10-14 WO claimed
US-5843618-A Hydrogen bond donating/accepting thermal solvents for image separation systems EASTMAN KODAK COMPANY (US) 1998-12-01 US claimed
EP-0692733-B1 Direct thermal recording process AGFA GEVAERT NV (BE) 1998-02-04 EP claimed
US-5582953-A IMAGING LAYER CONTAINING SILVER SALTS AND ORGANIC DIHYDROXYL-CONTAINING REDUCING AGENT THEREFOR AGFA-GEVAERT N.V. (BE) 1996-12-10 US claimed
EP-0692733-A2 Direct thermal recording process AGFA-GEVAERT N.V. (BE) 1996-01-17 EP claimed
EP-0142241-B1 DIHYDROXYBENZAMIDE DERIVATIVES HAVING ANTI-INFLAMMATORY ACTIVITY KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1987-12-02 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200205541-A1 METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AROMATIC COMPOUND KRT18, TUBB4A, TUBB4B LCK 539/4885CA2 2393/4885CA12 1543/4885
US-20230255906-A1 Targeting Serpin B9 in Cancer SERPINB10, SERPINB8, SERPINE1 LCK 4817/4885CA2 4819/4885CA12 4255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.